Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinlongkusu Injection vs Yinzhihuang Injection for Chronic Hepatitis B Jaundice
CTR20140244Phase 3Completed
- Sponsor
- Xida Yonghe Technology Development
- Start
- May 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gentiopicroside in Chronic Hepatitis B (CHB), jaundice, sponsored by Xida Yonghe Technology Development. Started May 2014; status: completed.
02
Drugs
gentiopicroside
03
Conditions
Chronic Hepatitis B (CHB)jaundice
Beyond the preview
Go deeper on CTR20140244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140244.